Arpida to slash jobs in wake of FDA setback for iclaprim

12/1/2008 | PharmaTimes (U.K.)

Arpida is laying off as many as 60 workers after FDA advisers declined to endorse approval of iclaprim, an injectable antibiotic. The Swiss company said it will consult with outside experts before deciding whether to continue developing the drug, which is designed to treat serious skin infections, including those involving methicillin-resistant Staphylococcus aureus.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL